Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.50 -0.7%	$187.12	$163.63 ▼ $218.66	$336.94B	0.48	6.25 million shs	3.71 million shs
AMGN Amgen	$298.25 +0.5%	$281.75	$253.30 ▼ $346.85	$159.62B	0.49	2.84 million shs	1.52 million shs
GILD Gilead Sciences	$111.28 -0.2%	$106.75	$66.01 ▼ $119.96	$138.71B	0.29	7.69 million shs	4.04 million shs
IQV IQVIA	$164.24 -0.2%	$150.32	$134.65 ▼ $252.88	$28.48B	1.3	1.65 million shs	674,106 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.45%	+2.77%	+2.14%	-5.23%	+14.95%
AMGN Amgen	+2.18%	+5.89%	+2.90%	-4.20%	-4.48%
GILD Gilead Sciences	-0.20%	+5.27%	+2.39%	-0.78%	+63.03%
IQV IQVIA	+1.36%	+3.76%	+18.47%	-1.72%	-20.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9057 of 5 stars	3.4	5.0	3.3	3.9	2.8	1.7	1.3
AMGN Amgen	4.451 of 5 stars	2.2	2.0	3.3	3.9	3.3	2.5	1.3
GILD Gilead Sciences	4.8434 of 5 stars	1.4	3.0	4.2	4.1	4.1	2.5	3.1
IQV IQVIA	4.9147 of 5 stars	4.4	2.0	0.0	4.6	3.2	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.50% Upside
AMGN Amgen	2.35	Hold	$307.82	3.21% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	-0.66% Downside
IQV IQVIA	2.75	Moderate Buy	$226.32	37.80% Upside

Current Analyst Ratings Breakdown

Latest ABBV, AMGN, GILD, and IQV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/23/2025	IQV IQVIA	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$188.00
5/22/2025	IQV IQVIA	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/19/2025	IQV IQVIA	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$232.00 ➝ $177.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.94	$14.84 per share	12.77	$1.90 per share	99.74
AMGN Amgen	$33.42B	4.80	$30.53 per share	9.77	$10.93 per share	27.29
GILD Gilead Sciences	$28.75B	4.81	$6.86 per share	16.23	$15.44 per share	7.21
IQV IQVIA	$15.41B	1.84	$16.57 per share	9.91	$33.43 per share	4.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.64	13.56	1.27	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
AMGN Amgen	$4.09B	$10.96	27.21	13.94	2.68	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.43	13.72	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
IQV IQVIA	$1.37B	$7.34	22.38	13.46	1.83	8.61%	29.16%	6.96%	7/28/2025 (Estimated)

Latest ABBV, AMGN, GILD, and IQV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/28/2025	Q2 2025	IQV IQVIA	$2.76	N/A	N/A	N/A	N/A	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
5/6/2025	Q1 2025	IQV IQVIA	$2.63	$2.70	+$0.07	$1.40	$3.77 billion	$3.83 billion
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.46%	N/A	279.15%	53 Years
AMGN Amgen	$9.52	3.19%	N/A	86.86%	14 Years
GILD Gilead Sciences	$3.16	2.84%	N/A	66.53%	10 Years
IQV IQVIA	N/A	N/A	N/A	N/A	N/A

Latest ABBV, AMGN, GILD, and IQV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
AMGN Amgen	8.70	1.17	0.88
GILD Gilead Sciences	1.16	1.37	1.23
IQV IQVIA	2.19	0.82	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
IQV IQVIA	89.62%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AMGN Amgen	0.76%
GILD Gilead Sciences	0.27%
IQV IQVIA	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AMGN Amgen	28,000	537.71 million	533.62 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
IQV IQVIA	88,000	173.00 million	170.23 million	Optionable

ABBV, AMGN, GILD, and IQV Headlines

Recent News About These Companies

IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

July 2 at 6:37 AM | marketbeat.com

IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Vontobel Holding Ltd.

July 2 at 6:18 AM | marketbeat.com

New York State Teachers Retirement System Sells 7,831 Shares of IQVIA Holdings Inc. (NYSE:IQV)

July 2 at 5:16 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Sells 1,592 Shares of IQVIA Holdings Inc. (NYSE:IQV)

July 2 at 4:31 AM | marketbeat.com

Is IQVIA Hldgs Gaining or Losing Market Support?

July 1 at 12:36 AM | benzinga.com

Understanding the FDA’s AI Guidance in Pharmacovigilance

July 1 at 12:36 AM | biospace.comB

Lupin shares in focus after FDA nod for post-eye surgery drug Loteprednol Etabonate Gel

July 1 at 12:36 AM | msn.com

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

July 1 at 7:00 AM | businesswire.com

Sequoia Financial Advisors LLC Sells 79,065 Shares of IQVIA Holdings Inc. (NYSE:IQV)

July 1 at 4:10 AM | marketbeat.com

Alembic Pharmaceuticals shares jump 14% on USFDA approval for cancer drug

June 30 at 8:33 PM | msn.com

Navigating AI’s promise and pitfalls in DTC advertising

June 30 at 8:33 PM | mmm-online.comM

Alembic Pharma shares surge as much as 12% on Monday; Here's why

June 30 at 3:58 AM | cnbctv18.comC

Alembic Pharma jumps after receiving USFDA nod for Doxorubicin Hydrochloride Injection

June 30 at 3:58 AM | msn.com

Alembic Pharmaceuticals gets USFDA nod for generic cancer treatment injection

June 30 at 3:58 AM | thehindubusinessline.com

Alembic Pharma Shares Soar 14%, Gets USFDA Nod For Key Cancer Drug

June 30 at 3:58 AM | msn.com

Alembic Pharmaceuticals Gains USFDA Nod for Cancer Fighting Injection

June 30 at 3:58 AM | devdiscourse.comD

Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $226.32

June 30 at 3:43 AM | americanbankingnews.com

KBC Group NV Has $106.44 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

June 29, 2025 | marketbeat.com

McGuire Investment Group LLC Has $9.33 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

June 29, 2025 | marketbeat.com

IQVIA Holdings Inc. (NYSE:IQV) Holdings Trimmed by Sumitomo Mitsui Trust Group Inc.

June 29, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

June 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABBV, AMGN, GILD, and IQV Company Descriptions

AbbVie NYSE:ABBV

$189.50 -1.25 (-0.66%)

Closing price 03:58 PM Eastern

Extended Trading

$188.90 -0.60 (-0.32%)

As of 04:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$298.25 +1.40 (+0.47%)

Closing price 03:58 PM Eastern

Extended Trading

$298.25 0.00 (0.00%)

As of 04:58 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$111.28 -0.24 (-0.21%)

Closing price 03:44 PM Eastern

Extended Trading

$111.28 0.00 (0.00%)

As of 04:52 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

IQVIA NYSE:IQV

$164.24 -0.41 (-0.25%)

Closing price 03:30 PM Eastern

Extended Trading

$163.14 -1.11 (-0.67%)

As of 04:58 PM Eastern

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time